leflunomide has been researched along with Lupus Erythematosus, Cutaneous, Subacute in 13 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Teriflunomide, the active metabolite of leflunomide, is a disease-modifying therapy drug used for the treatment of multiple sclerosis (MS), yet the complications associated with this drug remain not fully understood." | 5.41 | Subacute cutaneous lupus erythematosus as a rare complication of disease-modifying therapy administration in multiple sclerosis: case report. ( Feng, J; Qin, X; Xu, K; Yang, S; Yu, G; Zhang, M; Zheng, P, 2023) |
| "Leflunomide is an immunosuppressive agent that acts by inhibiting pyrimidine synthesis in lymphocytes and other rapidly proliferating cells, as well as by suppressing tumor necrosis factor-alpha-induced cellular responses." | 5.35 | Leflunomide-induced subacute cutaneous lupus erythematosus with erythema multiforme-like lesions. ( Alessi, E; Barbareschi, M; Del Papa, N; Marzano, AV; Ramoni, S, 2008) |
| "A skin eruption consistent with subacute cutaneous lupus erythematosus (SCLE) occurred in a patient taking leflunomide for rheumatoid arthritis." | 3.73 | Subacute cutaneous lupus erythematosus associated with leflunomide. ( David-Bajar, KM; Elias, AR; Tam, CC, 2005) |
| "Leflunomide is an immunosuppressive agent that acts by inhibiting pyrimidine synthesis in lymphocytes and other rapidly proliferating cells, as well as by suppressing tumor necrosis factor-alpha-induced cellular responses." | 1.35 | Leflunomide-induced subacute cutaneous lupus erythematosus with erythema multiforme-like lesions. ( Alessi, E; Barbareschi, M; Del Papa, N; Marzano, AV; Ramoni, S, 2008) |
| "Leflunomide is a new oral disease modifying antirheumatic drug with a good safety profile." | 1.33 | Lupus erythematosus with leflunomide: induction or reactivation? ( Gensburger, D; Kanitakis, J; Kawashima, M; Marotte, H; Miossec, P, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (61.54) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Xu, K | 1 |
| Zhang, M | 1 |
| Yang, S | 1 |
| Yu, G | 1 |
| Zheng, P | 1 |
| Qin, X | 1 |
| Feng, J | 1 |
| Blasco-Morente, G | 1 |
| Notario-Ferreira, I | 1 |
| Rueda-Villafranca, B | 1 |
| Tercedor-Sánchez, J | 1 |
| Sparsa, L | 1 |
| Afif, N | 1 |
| Goetz, J | 1 |
| Sordet, C | 1 |
| Chatelus, E | 1 |
| Lipsker, D | 1 |
| Sibilia, J | 1 |
| Kuhn, A | 1 |
| Ruland, V | 1 |
| Bonsmann, G | 1 |
| Kerr, OA | 1 |
| Murray, CS | 1 |
| Tidman, MJ | 1 |
| Heath, M | 1 |
| Raugi, GJ | 1 |
| Gensburger, D | 1 |
| Kawashima, M | 1 |
| Marotte, H | 1 |
| Kanitakis, J | 1 |
| Miossec, P | 1 |
| Goëb, V | 1 |
| Berthelot, JM | 1 |
| Joly, P | 1 |
| Mejjad, O | 1 |
| de Quatrebarbes, J | 1 |
| Reynaud-Hautin, C | 1 |
| Vittecoq, O | 1 |
| Le Loët, X | 1 |
| Chan, SK | 1 |
| Hazleman, BL | 1 |
| Burrows, NP | 1 |
| Elias, AR | 1 |
| Tam, CC | 1 |
| David-Bajar, KM | 1 |
| Suess, A | 1 |
| Sticherling, M | 1 |
| Marzano, AV | 1 |
| Ramoni, S | 1 |
| Del Papa, N | 1 |
| Barbareschi, M | 1 |
| Alessi, E | 1 |
3 reviews available for leflunomide and Lupus Erythematosus, Cutaneous, Subacute
| Article | Year |
|---|---|
Subacute cutaneous lupus erythematosus as a rare complication of disease-modifying therapy administration in multiple sclerosis: case report.
Topics: Adult; Female; Humans; Hydroxychloroquine; Leflunomide; Lupus Erythematosus, Cutaneous; Multiple Scl | 2023 |
Cutaneous lupus erythematosus: update of therapeutic options part II.
Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murin | 2011 |
Evidence-based evaluation of immunomodulatory therapy for the cutaneous manifestations of lupus.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimalarials; Azathioprine; Cladrib | 2004 |
10 other studies available for leflunomide and Lupus Erythematosus, Cutaneous, Subacute
| Article | Year |
|---|---|
Leflunomide: psoriasis, lupus.
Topics: Humans; Immunosuppressive Agents; Isoxazoles; Leflunomide; Lupus Erythematosus, Cutaneous; Psoriasis | 2013 |
[Subacute cutaneous lupus erythematosus induced by golimumab].
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Eruptions; Drug Therapy, C | 2015 |
Jessner-Kanof disease induced by leflunomide: a dermal variant of cutaneous lupus?
Topics: Antibodies, Antinuclear; Antirheumatic Agents; Chloroquine; Female; Gold; Humans; Interleukin 1 Rece | 2011 |
Subacute cutaneous lupus erythematosus associated with leflunomide.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Drug Eruptions; Humans; Isoxazoles; | 2004 |
Lupus erythematosus with leflunomide: induction or reactivation?
Topics: Antirheumatic Agents; Drug Eruptions; Female; Humans; Isoxazoles; Leflunomide; Lupus Erythematosus, | 2005 |
Leflunomide-induced subacute cutaneous lupus erythematosus.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Isoxazoles; Leflunomide; Lupus Erythema | 2005 |
Subacute cutaneous lupus erythematosus precipitated by leflunomide.
Topics: Female; Humans; Immunosuppressive Agents; Isoxazoles; Leflunomide; Lupus Erythematosus, Cutaneous; M | 2005 |
Subacute cutaneous lupus erythematosus associated with leflunomide.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Female; Humans; Isoxazoles; Leflunom | 2005 |
Leflunomide in subacute cutaneous lupus erythematosus - two sides of a coin.
Topics: Adult; Aged; Antirheumatic Agents; Diagnosis, Differential; Drug Eruptions; Enzyme Inhibitors; Eryth | 2008 |
Leflunomide-induced subacute cutaneous lupus erythematosus with erythema multiforme-like lesions.
Topics: Adjuvants, Immunologic; Adult; Antibodies, Antinuclear; Biopsy; Diagnosis, Differential; Erythema Mu | 2008 |